FDA is soliciting feedback on the potential use of new authorities under the SUPPORT Act to require certain immediate-release opioid analgesics be made available in fixed-quantity, unit-of-use blister packaging.
Statement on FDA’s request for information on requiring fixed-quantity blister packaging for certain opioid pain medicines to help decrease unnecessary exposure to opioids
More from FDA News AlertsMore posts in FDA News Alerts »
- Coronavirus (COVID-19) Update: June 22, 2021
- Prairie Wolf Spirits, Inc. Issues Voluntary Nationwide Recall of Prairie Wolf Distillery Hand Sanitizer Packed in 16.9 Oz. and 20 Oz Bottles Because They Resemble Drink Containers
- Sanit Technologies Adds Label Clarification to Existing Voluntary Hand Sanitizer Recall
- FDA Approves First Oral Blood Thinning Medication for Children